91 related articles for article (PubMed ID: 12193109)
1. Endothelin-1 acts as a survival factor in ovarian carcinoma cells.
Del Bufalo D; Di Castro V; Biroccio A; Salani D; Rosanò L; Spinella F; Bagnato A
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():302S-305S. PubMed ID: 12193109
[TBL] [Abstract][Full Text] [Related]
2. Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation.
Del Bufalo D; Di Castro V; Biroccio A; Varmi M; Salani D; Rosanò L; Trisciuoglio D; Spinella F; Bagnato A
Mol Pharmacol; 2002 Mar; 61(3):524-32. PubMed ID: 11854432
[TBL] [Abstract][Full Text] [Related]
3. Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth.
Bagnato A; Salani D; Di Castro V; Wu-Wong JR; Tecce R; Nicotra MR; Venuti A; Natali PG
Cancer Res; 1999 Feb; 59(3):720-7. PubMed ID: 9973223
[TBL] [Abstract][Full Text] [Related]
4. ABT-627, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma growth in vitro.
Salani D; Rosanò L; Di Castro V; Spinella F; Venuti A; Padley RJ; Nicotra MR; Natali PG; Bagnato A
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():318S-321S. PubMed ID: 12193113
[TBL] [Abstract][Full Text] [Related]
5. Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells.
Vacca F; Bagnato A; Catt KJ; Tecce R
Cancer Res; 2000 Sep; 60(18):5310-7. PubMed ID: 11016663
[TBL] [Abstract][Full Text] [Related]
6. ZD4054, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma cell proliferation.
Rosanò L; Di Castro V; Spinella F; Decandia S; Natali PG; Bagnato A
Exp Biol Med (Maywood); 2006 Jun; 231(6):1132-5. PubMed ID: 16741063
[TBL] [Abstract][Full Text] [Related]
7. Endothelin-1 promotes proteolytic activity of ovarian carcinoma.
Rosanò L; Salani D; Di Castro V; Spinella F; Natali PG; Bagnato A
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():306S-309S. PubMed ID: 12193110
[TBL] [Abstract][Full Text] [Related]
8. Targeting the endothelin axis in human melanoma: combination of endothelin receptor antagonism and alkylating agents.
Berger Y; Bernasconi CC; Juillerat-Jeanneret L
Exp Biol Med (Maywood); 2006 Jun; 231(6):1111-9. PubMed ID: 16741059
[TBL] [Abstract][Full Text] [Related]
9. ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo.
Rosanò L; Di Castro V; Spinella F; Nicotra MR; Natali PG; Bagnato A
Mol Cancer Ther; 2007 Jul; 6(7):2003-11. PubMed ID: 17620430
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma.
Rosanò L; Spinella F; Salani D; Di Castro V; Venuti A; Nicotra MR; Natali PG; Bagnato A
Cancer Res; 2003 May; 63(10):2447-53. PubMed ID: 12750265
[TBL] [Abstract][Full Text] [Related]
11. Endothelin expression and responsiveness in human ovarian carcinoma cell lines.
Moraitis S; Langdon SP; Miller WR
Eur J Cancer; 1997 Apr; 33(4):661-8. PubMed ID: 9274451
[TBL] [Abstract][Full Text] [Related]
12. Endothelin receptor blockade inhibits proliferation of Kaposi's sarcoma cells.
Bagnato A; Rosanò L; Di Castro V; Albini A; Salani D; Varmi M; Nicotra MR; Natali PG
Am J Pathol; 2001 Mar; 158(3):841-7. PubMed ID: 11238033
[TBL] [Abstract][Full Text] [Related]
13. Three vasoactive peptides, endothelin-1, adrenomedullin and urotensin-II, in human tumour cell lines of different origin: expression and effects on proliferation.
Takahashi K; Totsune K; Kitamuro T; Sone M; Murakami O; Shibahara S
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():35S-38S. PubMed ID: 12193050
[TBL] [Abstract][Full Text] [Related]
14. Endothelin receptor blockade inhibits the growth of human papillomavirus-associated cervical carcinoma.
Venuti A; Salani D; Cirilli A; Simeone P; Muller A; Flamini S; Padley R; Bagnato A
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():310S-313S. PubMed ID: 12193111
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells.
Spinella F; Rosanò L; Di Castro V; Nicotra MR; Natali PG; Bagnato A
Clin Cancer Res; 2004 Jul; 10(14):4670-9. PubMed ID: 15269139
[TBL] [Abstract][Full Text] [Related]
16. Autocrine actions of endothelin-1 as a growth factor in human ovarian carcinoma cells.
Bagnato A; Tecce R; Moretti C; Di Castro V; Spergel D; Catt KJ
Clin Cancer Res; 1995 Sep; 1(9):1059-66. PubMed ID: 9816080
[TBL] [Abstract][Full Text] [Related]
17. Endothelin-1 promotes cell survival in renal cell carcinoma through the ET(A) receptor.
Pflug BR; Zheng H; Udan MS; D'Antonio JM; Marshall FF; Brooks JD; Nelson JB
Cancer Lett; 2007 Feb; 246(1-2):139-48. PubMed ID: 16581180
[TBL] [Abstract][Full Text] [Related]
18. Endothelin-2 is a hypoxia-induced autocrine survival factor for breast tumor cells.
Grimshaw MJ; Naylor S; Balkwill FR
Mol Cancer Ther; 2002 Dec; 1(14):1273-81. PubMed ID: 12516960
[TBL] [Abstract][Full Text] [Related]
19. Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity.
Rosanò L; Di Castro V; Spinella F; Tortora G; Nicotra MR; Natali PG; Bagnato A
Cancer Res; 2007 Jul; 67(13):6351-9. PubMed ID: 17616694
[TBL] [Abstract][Full Text] [Related]
20. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Nicotra MR; Lucidi A; Ferrandina G; Natali PG; Bagnato A
Clin Cancer Res; 2011 Apr; 17(8):2350-60. PubMed ID: 21220476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
